APO Research
Talk to an analyst

APO RESEARCH · REPORT

Sustained Release Injectables

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Sustained Release Injectables Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025191 pages

Choose your research edition.

Industry ResearchSustained Release Injectables Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Sustained Release Injectables Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Sustained Release Injectables Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Sustained Release Injectables Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal Sustained Release Injectables Market Analysis and Forecast 2026-2032217 pages · $4,950 USD

Market perspective

The global Sustained Release Injectables market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Sustained Release Injectables is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Sustained Release Injectables is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Sustained Release Injectables is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Sustained Release Injectables is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Sustained Release Injectables include Sanofi, Novartis, Merck, Luye Pharma Group, Roche, Livzon Pharm, Eli Lilly, AstraZeneca and Xbrane Biopharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Sustained Release Injectables market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Sustained Release Injectables and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Sustained Release Injectables revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Sustained Release Injectables market size, projected growth trends, production technologies, key applications, and end-use industries.

Sustained Release Injectables Segment by Company

Sanofi

Novartis

Merck

Luye Pharma Group

Roche

Livzon Pharm

Eli Lilly

AstraZeneca

Xbrane Biopharma

Taiwan Liposome Company (TLC)

Recipharm AB

PhaseBio Pharmaceuticals

Pacira

OctoPlus

Oakwood Laboratories/PharmaSophia

NanOlogy

Janssen

Ipsen

InnoCore Pharmaceuticals

Enzon

Durect

Critical Pharmaceuticals

Camurus

Biomarin

Avadel

Aurobindo

Ascendis Pharma

AntriaBio

Amylin Pharmaceuticals

Alkermes

Sustained Release Injectables Segment by Type

Gels

Microparticles

Implants

Sustained Release Injectables Segment by Application

Oncology

CNS

Acromegaly

Ophthalmology

Diabetes

Reproductive Health

Rheumatology

Leukemia

Others

Sustained Release Injectables Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sustained Release Injectables market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Sustained Release Injectables and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sustained Release Injectables.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Sustained Release Injectables in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Sustained Release Injectables industry.

Chapter 3: Detailed analysis of Sustained Release Injectables companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Sustained Release Injectablesrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Sustained Release Injectables Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Gels Table 3. Key Players of Microparticles Table 4. Key Players of Implants Table 4. Global Sustained Release Injectables Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Oncology Table 6. Key Players of CNS Table 7. Key Players of Acromegaly Table 8. Key Players of Ophthalmology Table 9. Key Players of Diabetes Table 10. Key Players of Reproductive Health Table 11. Key Players of Rheumatology Table 12. Key Players of Leukemia Table 13. Key Players of Others Table 14. Global Sustained Release Injectables Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Sustained Release Injectables Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Sustained Release Injectables Market Share by Region (2021-2026) Table 17. Global Sustained Release Injectables Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Sustained Release Injectables Market Share by Region (2027-2032) Table 19. Sustained Release Injectables Industry Trends Table 20. Sustained Release Injectables Industry Drivers Table 21. Sustained Release Injectables Industry Opportunities and Challenges Table 22. Sustained Release Injectables Industry Restraints Table 23. Global Sustained Release Injectables Revenue by Company (US$ Million) & (2021-2026) Table 24. Global Sustained Release Injectables Revenue Market Share by Company (2021-2026) Table 25. Global Sustained Release Injectables Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 26. Global Sustained Release Injectables Key Company Head Office and Area Served Table 27. Global Sustained Release Injectables Company, Product Type & Application Table 28. Global Sustained Release Injectables Company Establishment Date Table 29. Global Company Market Concentration Ratio (CR5 and HHI) Table 30. Global Sustained Release Injectables by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 31. Global Sustained Release Injectables Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Sustained Release Injectables Market Size by Type (2021-2026) & (US$ Million) Table 33. Global Sustained Release Injectables Market Size by Type (2027-2032) & (US$ Million) Table 34. Global Sustained Release Injectables Revenue Market Share by Type (2021-2026) Table 35. Global Sustained Release Injectables Revenue Market Share by Type (2027-2032) Table 36. Global Sustained Release Injectables Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Sustained Release Injectables Market Size by Application (2021-2026) & (US$ Million) Table 38. Global Sustained Release Injectables Market Size by Application (2027-2032) & (US$ Million) Table 39. Global Sustained Release Injectables Revenue Market Share by Application (2021-2026) Table 40. Global Sustained Release Injectables Revenue Market Share by Application (2027-2032) Table 41. Sanofi Company Information Table 42. Sanofi Business Overview Table 43. Sanofi Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Sanofi Sustained Release Injectables Product Portfolio Table 45. Sanofi Recent Development Table 46. Novartis Company Information Table 47. Novartis Business Overview Table 48. Novartis Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Novartis Sustained Release Injectables Product Portfolio Table 50. Novartis Recent Development Table 51. Merck Company Information Table 52. Merck Business Overview Table 53. Merck Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Merck Sustained Release Injectables Product Portfolio Table 55. Merck Recent Development Table 56. Luye Pharma Group Company Information Table 57. Luye Pharma Group Business Overview Table 58. Luye Pharma Group Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Luye Pharma Group Sustained Release Injectables Product Portfolio Table 60. Luye Pharma Group Recent Development Table 61. Roche Company Information Table 62. Roche Business Overview Table 63. Roche Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Roche Sustained Release Injectables Product Portfolio Table 65. Roche Recent Development Table 66. Livzon Pharm Company Information Table 67. Livzon Pharm Business Overview Table 68. Livzon Pharm Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Livzon Pharm Sustained Release Injectables Product Portfolio Table 70. Livzon Pharm Recent Development Table 71. Eli Lilly Company Information Table 72. Eli Lilly Business Overview Table 73. Eli Lilly Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Eli Lilly Sustained Release Injectables Product Portfolio Table 75. Eli Lilly Recent Development Table 76. AstraZeneca Company Information Table 77. AstraZeneca Business Overview Table 78. AstraZeneca Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. AstraZeneca Sustained Release Injectables Product Portfolio Table 80. AstraZeneca Recent Development Table 81. Xbrane Biopharma Company Information Table 82. Xbrane Biopharma Business Overview Table 83. Xbrane Biopharma Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Xbrane Biopharma Sustained Release Injectables Product Portfolio Table 85. Xbrane Biopharma Recent Development Table 86. Taiwan Liposome Company (TLC) Company Information Table 87. Taiwan Liposome Company (TLC) Business Overview Table 88. Taiwan Liposome Company (TLC) Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. Taiwan Liposome Company (TLC) Sustained Release Injectables Product Portfolio Table 90. Taiwan Liposome Company (TLC) Recent Development Table 91. Recipharm AB Company Information Table 92. Recipharm AB Business Overview Table 93. Recipharm AB Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 94. Recipharm AB Sustained Release Injectables Product Portfolio Table 95. Recipharm AB Recent Development Table 96. PhaseBio Pharmaceuticals Company Information Table 97. PhaseBio Pharmaceuticals Business Overview Table 98. PhaseBio Pharmaceuticals Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 99. PhaseBio Pharmaceuticals Sustained Release Injectables Product Portfolio Table 100. PhaseBio Pharmaceuticals Recent Development Table 101. Pacira Company Information Table 102. Pacira Business Overview Table 103. Pacira Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 104. Pacira Sustained Release Injectables Product Portfolio Table 105. Pacira Recent Development Table 106. OctoPlus Company Information Table 107. OctoPlus Business Overview Table 108. OctoPlus Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 109. OctoPlus Sustained Release Injectables Product Portfolio Table 110. OctoPlus Recent Development Table 111. Oakwood Laboratories/PharmaSophia Company Information Table 112. Oakwood Laboratories/PharmaSophia Business Overview Table 113. Oakwood Laboratories/PharmaSophia Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 114. Oakwood Laboratories/PharmaSophia Sustained Release Injectables Product Portfolio Table 115. Oakwood Laboratories/PharmaSophia Recent Development Table 116. NanOlogy Company Information Table 117. NanOlogy Business Overview Table 118. NanOlogy Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 119. NanOlogy Sustained Release Injectables Product Portfolio Table 120. NanOlogy Recent Development Table 121. Janssen Company Information Table 122. Janssen Business Overview Table 123. Janssen Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 124. Janssen Sustained Release Injectables Product Portfolio Table 125. Janssen Recent Development Table 126. Ipsen Company Information Table 127. Ipsen Business Overview Table 128. Ipsen Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 129. Ipsen Sustained Release Injectables Product Portfolio Table 130. Ipsen Recent Development Table 131. InnoCore Pharmaceuticals Company Information Table 132. InnoCore Pharmaceuticals Business Overview Table 133. InnoCore Pharmaceuticals Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 134. InnoCore Pharmaceuticals Sustained Release Injectables Product Portfolio Table 135. InnoCore Pharmaceuticals Recent Development Table 136. Enzon Company Information Table 137. Enzon Business Overview Table 138. Enzon Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 139. Enzon Sustained Release Injectables Product Portfolio Table 140. Enzon Recent Development Table 141. Durect Company Information Table 142. Durect Business Overview Table 143. Durect Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 144. Durect Sustained Release Injectables Product Portfolio Table 145. Durect Recent Development Table 146. Critical Pharmaceuticals Company Information Table 147. Critical Pharmaceuticals Business Overview Table 148. Critical Pharmaceuticals Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 149. Critical Pharmaceuticals Sustained Release Injectables Product Portfolio Table 150. Critical Pharmaceuticals Recent Development Table 151. Camurus Company Information Table 152. Camurus Business Overview Table 153. Camurus Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 154. Camurus Sustained Release Injectables Product Portfolio Table 155. Camurus Recent Development Table 156. Biomarin Company Information Table 157. Biomarin Business Overview Table 158. Biomarin Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 159. Biomarin Sustained Release Injectables Product Portfolio Table 160. Biomarin Recent Development Table 161. Avadel Company Information Table 162. Avadel Business Overview Table 163. Avadel Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 164. Avadel Sustained Release Injectables Product Portfolio Table 165. Avadel Recent Development Table 166. Aurobindo Company Information Table 167. Aurobindo Business Overview Table 168. Aurobindo Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 169. Aurobindo Sustained Release Injectables Product Portfolio Table 170. Aurobindo Recent Development Table 171. Ascendis Pharma Company Information Table 172. Ascendis Pharma Business Overview Table 173. Ascendis Pharma Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 174. Ascendis Pharma Sustained Release Injectables Product Portfolio Table 175. Ascendis Pharma Recent Development Table 176. AntriaBio Company Information Table 177. AntriaBio Business Overview Table 178. AntriaBio Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 179. AntriaBio Sustained Release Injectables Product Portfolio Table 180. AntriaBio Recent Development Table 181. Amylin Pharmaceuticals Company Information Table 182. Amylin Pharmaceuticals Business Overview Table 183. Amylin Pharmaceuticals Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 184. Amylin Pharmaceuticals Sustained Release Injectables Product Portfolio Table 185. Amylin Pharmaceuticals Recent Development Table 186. Alkermes Company Information Table 187. Alkermes Business Overview Table 188. Alkermes Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026) Table 189. Alkermes Sustained Release Injectables Product Portfolio Table 190. Alkermes Recent Development Table 191. North America Sustained Release Injectables Market Size by Type (2021-2026) & (US$ Million) Table 192. North America Sustained Release Injectables Market Size by Type (2027-2032) & (US$ Million) Table 193. North America Sustained Release Injectables Market Size by Application (2021-2026) & (US$ Million) Table 194. North America Sustained Release Injectables Market Size by Application (2027-2032) & (US$ Million) Table 195. North America Sustained Release Injectables Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 196. North America Sustained Release Injectables Market Size by Country (2021-2026) Table 197. North America Sustained Release Injectables Market Size by Country (2027-2032) Table 198. Europe Sustained Release Injectables Market Size by Type (2021-2026) & (US$ Million) Table 199. Europe Sustained Release Injectables Market Size by Type (2027-2032) & (US$ Million) Table 200. Europe Sustained Release Injectables Market Size by Application (2021-2026) & (US$ Million) Table 201. Europe Sustained Release Injectables Market Size by Application (2027-2032) & (US$ Million) Table 202. Europe Sustained Release Injectables Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 203. Europe Sustained Release Injectables Market Size by Country (2021-2026) Table 204. Europe Sustained Release Injectables Market Size by Country (2027-2032) Table 205. China Sustained Release Injectables Market Size by Type (2021-2026) & (US$ Million) Table 206. China Sustained Release Injectables Market Size by Type (2027-2032) & (US$ Million) Table 207. China Sustained Release Injectables Market Size by Application (2021-2026) & (US$ Million) Table 208. China Sustained Release Injectables Market Size by Application (2027-2032) & (US$ Million) Table 209. Asia Sustained Release Injectables Market Size by Type (2021-2026) & (US$ Million) Table 210. Asia Sustained Release Injectables Market Size by Type (2027-2032) & (US$ Million) Table 211. Asia Sustained Release Injectables Market Size by Application (2021-2026) & (US$ Million) Table 212. Asia Sustained Release Injectables Market Size by Application (2027-2032) & (US$ Million) Table 213. Asia Sustained Release Injectables Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 214. Asia Sustained Release Injectables Market Size by Country (2021-2026) Table 215. Asia Sustained Release Injectables Market Size by Country (2027-2032) Table 216. South America, Middle East & Africa Sustained Release Injectables Market Size by Type (2021-2026) & (US$ Million) Table 217. South America, Middle East & Africa Sustained Release Injectables Market Size by Type (2027-2032) & (US$ Million) Table 218. South America, Middle East & Africa Sustained Release Injectables Market Size by Application (2021-2026) & (US$ Million) Table 219. South America, Middle East & Africa Sustained Release Injectables Market Size by Application (2027-2032) & (US$ Million) Table 220. South America, Middle East & Africa Sustained Release Injectables Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 221. South America, Middle East & Africa Sustained Release Injectables Market Size by Country (2021-2026) Table 222. South America, Middle East & Africa Sustained Release Injectables Market Size by Country (2027-2032) Table 223. Research Programs/Design for This Report Table 224. Authors List of This Report Table 225. Secondary Sources Table 226. Primary Sources List of Figures Figure 1. Sustained Release Injectables Product Image Figure 2. Global Sustained Release Injectables Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Sustained Release Injectables Market Share by Type: 2025 VS 2032 Figure 4. Gels Image Figure 5. Microparticles Image Figure 6. Implants Image Figure 7. Global Sustained Release Injectables Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 8. Global Sustained Release Injectables Market Share by Application: 2025 VS 2032 Figure 9. Oncology Image Figure 10. CNS Image Figure 11. Acromegaly Image Figure 12. Ophthalmology Image Figure 13. Diabetes Image Figure 14. Reproductive Health Image Figure 15. Rheumatology Image Figure 16. Leukemia Image Figure 17. Others Image Figure 18. Global Sustained Release Injectables Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 19. Global Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 20. Global Sustained Release Injectables Market Share by Region: 2025 VS 2032 Figure 21. Years Considered Figure 22. Global Sustained Release Injectables Market Share by Players in 2025 Figure 23. Global Top 5 and 10 Sustained Release Injectables Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Global Sustained Release Injectables Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Sustained Release Injectables Revenue Market Share by Type (2021-2032) Figure 27. Global Sustained Release Injectables Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Sustained Release Injectables Revenue Market Share by Application (2021-2032) Figure 29. North America Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 30. North America Sustained Release Injectables Market Share by Type (2021-2032) Figure 31. North America Sustained Release Injectables Market Share by Application (2021-2032) Figure 32. North America Sustained Release Injectables Market Share by Country (2021-2032) Figure 33. United States Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 34. Canada Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 35. Mexico Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 36. Europe Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 37. Europe Sustained Release Injectables Market Share by Type (2021-2032) Figure 38. Europe Sustained Release Injectables Market Share by Application (2021-2032) Figure 39. Europe Sustained Release Injectables Market Share by Country (2021-2032) Figure 40. Germany Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 41. France Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 42. U.K. Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 43. Italy Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 44. Russia Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 45. Nordic Countries Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 46. China Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 47. China Sustained Release Injectables Market Share by Type (2021-2032) Figure 48. China Sustained Release Injectables Market Share by Application (2021-2032) Figure 49. Asia Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 50. Asia Sustained Release Injectables Market Share by Type (2021-2032) Figure 51. Asia Sustained Release Injectables Market Share by Application (2021-2032) Figure 52. Asia Sustained Release Injectables Market Share by Country (2021-2032) Figure 53. Japan Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 54. South Korea Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 55. Taiwan Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 56. Southeast Asia Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 57. India Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 58. Australia Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 59. South America, Middle East & Africa Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 60. South America, Middle East & Africa Sustained Release Injectables Market Share by Type (2021-2032) Figure 61. South America, Middle East & Africa Sustained Release Injectables Market Share by Application (2021-2032) Figure 62. South America, Middle East & Africa Sustained Release Injectables Market Share by Country (2021-2032) Figure 63. Brazil Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 64. South Africa Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 65. Saudi Arabia Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 66. Turkey Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 67. Argentina Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 68. UAE Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 69. Egypt Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 70. Chile Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Gels
  • Microparticles
  • Implants
Applications
  • Oncology
  • CNS
  • Acromegaly
  • Ophthalmology
  • Diabetes
  • Reproductive Health
  • Rheumatology
  • Leukemia
  • Others
Companies covered
  • Sanofi
  • Novartis
  • Merck
  • Luye Pharma Group
  • Roche
  • Livzon Pharm
  • Eli Lilly
  • AstraZeneca
  • Xbrane Biopharma
  • Taiwan Liposome Company (TLC)
  • Recipharm AB
  • PhaseBio Pharmaceuticals
  • Pacira
  • OctoPlus
  • Oakwood Laboratories/PharmaSophia
  • NanOlogy
  • Janssen
  • Ipsen
  • InnoCore Pharmaceuticals
  • Enzon
  • Durect
  • Critical Pharmaceuticals
  • Camurus
  • Biomarin
  • Avadel
  • Aurobindo
  • Ascendis Pharma
  • AntriaBio
  • Amylin Pharmaceuticals
  • Alkermes

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Sustained Release Injectables Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Gels
  5. 1.2.3 Microparticles
  6. 1.2.4 Implants
  7. 1.3 Market Analysis by Application
  8. 1.3.1 Global Sustained Release Injectables Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  9. 1.3.2 Oncology
  10. 1.3.3 CNS
  11. 1.3.4 Acromegaly
  12. 1.3.5 Ophthalmology
  13. 1.3.6 Diabetes
  14. 1.3.7 Reproductive Health
  15. 1.3.8 Rheumatology
  16. 1.3.9 Leukemia
  17. 1.3.10 Others
  18. 1.4 Global Market Growth Prospects
  19. 1.5 Global Sustained Release Injectables Growth Trends by Region
  20. 1.5.1 Global Sustained Release Injectables Market Size by Region: 2021 VS 2025 VS 2032
  21. 1.5.2 Sustained Release Injectables Market Size by Region (2021-2026)
  22. 1.5.3 Sustained Release Injectables Market Size by Region (2027-2032)
  23. 1.6 Assumptions and Limitations
  24. 1.7 Study Goals and Objectives
  25. 1.8 Years Considered
2 Global Sustained Release Injectables Market Dynamics
  1. 2.1 Sustained Release Injectables Industry Trends
  2. 2.2 Sustained Release Injectables Industry Drivers
  3. 2.3 Sustained Release Injectables Industry Opportunities and Challenges
  4. 2.4 Sustained Release Injectables Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Sustained Release Injectables Revenue by Company (2021-2026)
  2. 3.2 Global Sustained Release Injectables Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Sustained Release Injectables Key Company Head office and Area Served
  4. 3.4 Global Sustained Release Injectables Company, Product Type & Application
  5. 3.5 Global Sustained Release Injectables Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Sustained Release Injectables Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Sustained Release Injectables Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Sustained Release Injectables Tier 1, Tier 2, and Tier 3
4 Sustained Release Injectables Market by Type
  1. 4.1 Global Sustained Release Injectables Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Sustained Release Injectables Market Size by Type (2021-2032)
  3. 4.3 Global Sustained Release Injectables Market Size Share by Type (2021-2032)
5 Sustained Release Injectables Market by Application
  1. 5.1 Global Sustained Release Injectables Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Sustained Release Injectables Market Size by Application (2021-2032)
  3. 5.3 Global Sustained Release Injectables Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Sanofi
  2. 6.1.1 Sanofi Company Information
  3. 6.1.2 Sanofi Business Overview
  4. 6.1.3 Sanofi Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Sanofi Sustained Release Injectables Product Portfolio
  6. 6.1.5 Sanofi Recent Developments
  7. 6.2 Novartis
  8. 6.2.1 Novartis Company Information
  9. 6.2.2 Novartis Business Overview
  10. 6.2.3 Novartis Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Novartis Sustained Release Injectables Product Portfolio
  12. 6.2.5 Novartis Recent Developments
  13. 6.3 Merck
  14. 6.3.1 Merck Company Information
  15. 6.3.2 Merck Business Overview
  16. 6.3.3 Merck Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Merck Sustained Release Injectables Product Portfolio
  18. 6.3.5 Merck Recent Developments
  19. 6.4 Luye Pharma Group
  20. 6.4.1 Luye Pharma Group Company Information
  21. 6.4.2 Luye Pharma Group Business Overview
  22. 6.4.3 Luye Pharma Group Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Luye Pharma Group Sustained Release Injectables Product Portfolio
  24. 6.4.5 Luye Pharma Group Recent Developments
  25. 6.5 Roche
  26. 6.5.1 Roche Company Information
  27. 6.5.2 Roche Business Overview
  28. 6.5.3 Roche Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Roche Sustained Release Injectables Product Portfolio
  30. 6.5.5 Roche Recent Developments
  31. 6.6 Livzon Pharm
  32. 6.6.1 Livzon Pharm Company Information
  33. 6.6.2 Livzon Pharm Business Overview
  34. 6.6.3 Livzon Pharm Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Livzon Pharm Sustained Release Injectables Product Portfolio
  36. 6.6.5 Livzon Pharm Recent Developments
  37. 6.7 Eli Lilly
  38. 6.7.1 Eli Lilly Company Information
  39. 6.7.2 Eli Lilly Business Overview
  40. 6.7.3 Eli Lilly Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Eli Lilly Sustained Release Injectables Product Portfolio
  42. 6.7.5 Eli Lilly Recent Developments
  43. 6.8 AstraZeneca
  44. 6.8.1 AstraZeneca Company Information
  45. 6.8.2 AstraZeneca Business Overview
  46. 6.8.3 AstraZeneca Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 AstraZeneca Sustained Release Injectables Product Portfolio
  48. 6.8.5 AstraZeneca Recent Developments
  49. 6.9 Xbrane Biopharma
  50. 6.9.1 Xbrane Biopharma Company Information
  51. 6.9.2 Xbrane Biopharma Business Overview
  52. 6.9.3 Xbrane Biopharma Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Xbrane Biopharma Sustained Release Injectables Product Portfolio
  54. 6.9.5 Xbrane Biopharma Recent Developments
  55. 6.10 Taiwan Liposome Company (TLC)
  56. 6.10.1 Taiwan Liposome Company (TLC) Company Information
  57. 6.10.2 Taiwan Liposome Company (TLC) Business Overview
  58. 6.10.3 Taiwan Liposome Company (TLC) Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Taiwan Liposome Company (TLC) Sustained Release Injectables Product Portfolio
  60. 6.10.5 Taiwan Liposome Company (TLC) Recent Developments
  61. 6.11 Recipharm AB
  62. 6.11.1 Recipharm AB Company Information
  63. 6.11.2 Recipharm AB Business Overview
  64. 6.11.3 Recipharm AB Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Recipharm AB Sustained Release Injectables Product Portfolio
  66. 6.11.5 Recipharm AB Recent Developments
  67. 6.12 PhaseBio Pharmaceuticals
  68. 6.12.1 PhaseBio Pharmaceuticals Company Information
  69. 6.12.2 PhaseBio Pharmaceuticals Business Overview
  70. 6.12.3 PhaseBio Pharmaceuticals Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 PhaseBio Pharmaceuticals Sustained Release Injectables Product Portfolio
  72. 6.12.5 PhaseBio Pharmaceuticals Recent Developments
  73. 6.13 Pacira
  74. 6.13.1 Pacira Company Information
  75. 6.13.2 Pacira Business Overview
  76. 6.13.3 Pacira Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Pacira Sustained Release Injectables Product Portfolio
  78. 6.13.5 Pacira Recent Developments
  79. 6.14 OctoPlus
  80. 6.14.1 OctoPlus Company Information
  81. 6.14.2 OctoPlus Business Overview
  82. 6.14.3 OctoPlus Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 OctoPlus Sustained Release Injectables Product Portfolio
  84. 6.14.5 OctoPlus Recent Developments
  85. 6.15 Oakwood Laboratories/PharmaSophia
  86. 6.15.1 Oakwood Laboratories/PharmaSophia Company Information
  87. 6.15.2 Oakwood Laboratories/PharmaSophia Business Overview
  88. 6.15.3 Oakwood Laboratories/PharmaSophia Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Oakwood Laboratories/PharmaSophia Sustained Release Injectables Product Portfolio
  90. 6.15.5 Oakwood Laboratories/PharmaSophia Recent Developments
  91. 6.16 NanOlogy
  92. 6.16.1 NanOlogy Company Information
  93. 6.16.2 NanOlogy Business Overview
  94. 6.16.3 NanOlogy Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 NanOlogy Sustained Release Injectables Product Portfolio
  96. 6.16.5 NanOlogy Recent Developments
  97. 6.17 Janssen
  98. 6.17.1 Janssen Company Information
  99. 6.17.2 Janssen Business Overview
  100. 6.17.3 Janssen Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  101. 6.17.4 Janssen Sustained Release Injectables Product Portfolio
  102. 6.17.5 Janssen Recent Developments
  103. 6.18 Ipsen
  104. 6.18.1 Ipsen Company Information
  105. 6.18.2 Ipsen Business Overview
  106. 6.18.3 Ipsen Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  107. 6.18.4 Ipsen Sustained Release Injectables Product Portfolio
  108. 6.18.5 Ipsen Recent Developments
  109. 6.19 InnoCore Pharmaceuticals
  110. 6.19.1 InnoCore Pharmaceuticals Company Information
  111. 6.19.2 InnoCore Pharmaceuticals Business Overview
  112. 6.19.3 InnoCore Pharmaceuticals Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  113. 6.19.4 InnoCore Pharmaceuticals Sustained Release Injectables Product Portfolio
  114. 6.19.5 InnoCore Pharmaceuticals Recent Developments
  115. 6.20 Enzon
  116. 6.20.1 Enzon Company Information
  117. 6.20.2 Enzon Business Overview
  118. 6.20.3 Enzon Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  119. 6.20.4 Enzon Sustained Release Injectables Product Portfolio
  120. 6.20.5 Enzon Recent Developments
  121. 6.21 Durect
  122. 6.21.1 Durect Company Information
  123. 6.21.2 Durect Business Overview
  124. 6.21.3 Durect Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  125. 6.21.4 Durect Sustained Release Injectables Product Portfolio
  126. 6.21.5 Durect Recent Developments
  127. 6.22 Critical Pharmaceuticals
  128. 6.22.1 Critical Pharmaceuticals Company Information
  129. 6.22.2 Critical Pharmaceuticals Business Overview
  130. 6.22.3 Critical Pharmaceuticals Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  131. 6.22.4 Critical Pharmaceuticals Sustained Release Injectables Product Portfolio
  132. 6.22.5 Critical Pharmaceuticals Recent Developments
  133. 6.23 Camurus
  134. 6.23.1 Camurus Company Information
  135. 6.23.2 Camurus Business Overview
  136. 6.23.3 Camurus Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  137. 6.23.4 Camurus Sustained Release Injectables Product Portfolio
  138. 6.23.5 Camurus Recent Developments
  139. 6.24 Biomarin
  140. 6.24.1 Biomarin Company Information
  141. 6.24.2 Biomarin Business Overview
  142. 6.24.3 Biomarin Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  143. 6.24.4 Biomarin Sustained Release Injectables Product Portfolio
  144. 6.24.5 Biomarin Recent Developments
  145. 6.25 Avadel
  146. 6.25.1 Avadel Company Information
  147. 6.25.2 Avadel Business Overview
  148. 6.25.3 Avadel Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  149. 6.25.4 Avadel Sustained Release Injectables Product Portfolio
  150. 6.25.5 Avadel Recent Developments
  151. 6.26 Aurobindo
  152. 6.26.1 Aurobindo Company Information
  153. 6.26.2 Aurobindo Business Overview
  154. 6.26.3 Aurobindo Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  155. 6.26.4 Aurobindo Sustained Release Injectables Product Portfolio
  156. 6.26.5 Aurobindo Recent Developments
  157. 6.27 Ascendis Pharma
  158. 6.27.1 Ascendis Pharma Company Information
  159. 6.27.2 Ascendis Pharma Business Overview
  160. 6.27.3 Ascendis Pharma Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  161. 6.27.4 Ascendis Pharma Sustained Release Injectables Product Portfolio
  162. 6.27.5 Ascendis Pharma Recent Developments
  163. 6.28 AntriaBio
  164. 6.28.1 AntriaBio Company Information
  165. 6.28.2 AntriaBio Business Overview
  166. 6.28.3 AntriaBio Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  167. 6.28.4 AntriaBio Sustained Release Injectables Product Portfolio
  168. 6.28.5 AntriaBio Recent Developments
  169. 6.29 Amylin Pharmaceuticals
  170. 6.29.1 Amylin Pharmaceuticals Company Information
  171. 6.29.2 Amylin Pharmaceuticals Business Overview
  172. 6.29.3 Amylin Pharmaceuticals Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  173. 6.29.4 Amylin Pharmaceuticals Sustained Release Injectables Product Portfolio
  174. 6.29.5 Amylin Pharmaceuticals Recent Developments
  175. 6.30 Alkermes
  176. 6.30.1 Alkermes Company Information
  177. 6.30.2 Alkermes Business Overview
  178. 6.30.3 Alkermes Sustained Release Injectables Revenue and Gross Margin (US$ Million) & (2021-2026)
  179. 6.30.4 Alkermes Sustained Release Injectables Product Portfolio
  180. 6.30.5 Alkermes Recent Developments
7 North America
  1. 7.1 North America Sustained Release Injectables Market Size (2021-2032)
  2. 7.2 North America Sustained Release Injectables Market Size by Type
  3. 7.2.1 North America Sustained Release Injectables Market Size by Type (2021-2026)
  4. 7.2.2 North America Sustained Release Injectables Market Size by Type (2027-2032)
  5. 7.2.3 North America Sustained Release Injectables Market Share by Type (2021-2032)
  6. 7.3 North America Sustained Release Injectables Market Size by Application
  7. 7.3.1 North America Sustained Release Injectables Market Size by Application (2021-2026)
  8. 7.3.2 North America Sustained Release Injectables Market Size by Application (2027-2032)
  9. 7.3.3 North America Sustained Release Injectables Market Share by Application (2021-2032)
  10. 7.4 North America Sustained Release Injectables Market Size by Country
  11. 7.4.1 North America Sustained Release Injectables Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Sustained Release Injectables Market Size by Country (2021-2026)
  13. 7.4.3 North America Sustained Release Injectables Market Size by Country (2027-2032)
  14. 7.4.4 North America Sustained Release Injectables Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Sustained Release Injectables Market Size (2021-2032)
  2. 8.2 Europe Sustained Release Injectables Market Size by Type
  3. 8.2.1 Europe Sustained Release Injectables Market Size by Type (2021-2026)
  4. 8.2.2 Europe Sustained Release Injectables Market Size by Type (2027-2032)
  5. 8.2.3 Europe Sustained Release Injectables Market Share by Type (2021-2032)
  6. 8.3 Europe Sustained Release Injectables Market Size by Application
  7. 8.3.1 Europe Sustained Release Injectables Market Size by Application (2021-2026)
  8. 8.3.2 Europe Sustained Release Injectables Market Size by Application (2027-2032)
  9. 8.3.3 Europe Sustained Release Injectables Market Share by Application (2021-2032)
  10. 8.4 Europe Sustained Release Injectables Market Size by Country
  11. 8.4.1 Europe Sustained Release Injectables Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Sustained Release Injectables Market Size by Country (2021-2026)
  13. 8.4.3 Europe Sustained Release Injectables Market Size by Country (2027-2032)
  14. 8.4.4 Europe Sustained Release Injectables Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Sustained Release Injectables Market Size (2021-2032)
  2. 9.2 China Sustained Release Injectables Market Size by Type
  3. 9.2.1 China Sustained Release Injectables Market Size by Type (2021-2026)
  4. 9.2.2 China Sustained Release Injectables Market Size by Type (2027-2032)
  5. 9.2.3 China Sustained Release Injectables Market Share by Type (2021-2032)
  6. 9.3 China Sustained Release Injectables Market Size by Application
  7. 9.3.1 China Sustained Release Injectables Market Size by Application (2021-2026)
  8. 9.3.2 China Sustained Release Injectables Market Size by Application (2027-2032)
  9. 9.3.3 China Sustained Release Injectables Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Sustained Release Injectables Market Size (2021-2032)
  2. 10.2 Asia Sustained Release Injectables Market Size by Type
  3. 10.2.1 Asia Sustained Release Injectables Market Size by Type (2021-2026)
  4. 10.2.2 Asia Sustained Release Injectables Market Size by Type (2027-2032)
  5. 10.2.3 Asia Sustained Release Injectables Market Share by Type (2021-2032)
  6. 10.3 Asia Sustained Release Injectables Market Size by Application
  7. 10.3.1 Asia Sustained Release Injectables Market Size by Application (2021-2026)
  8. 10.3.2 Asia Sustained Release Injectables Market Size by Application (2027-2032)
  9. 10.3.3 Asia Sustained Release Injectables Market Share by Application (2021-2032)
  10. 10.4 Asia Sustained Release Injectables Market Size by Country
  11. 10.4.1 Asia Sustained Release Injectables Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Sustained Release Injectables Market Size by Country (2021-2026)
  13. 10.4.3 Asia Sustained Release Injectables Market Size by Country (2027-2032)
  14. 10.4.4 Asia Sustained Release Injectables Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Sustained Release Injectables Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Sustained Release Injectables Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Sustained Release Injectables Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Sustained Release Injectables Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Sustained Release Injectables Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Sustained Release Injectables Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Sustained Release Injectables Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Sustained Release Injectables Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Sustained Release Injectables Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Sustained Release Injectables Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Sustained Release Injectables Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Sustained Release Injectables Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Sustained Release Injectables Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Sustained Release Injectables Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst